Dynorphin A (1-17)

SCHEMBL29599476

CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

	gene	UniProt	supporting neighbours	confidence
▸	OPRD1	P41143	8/20	0.70

▸	F2	P00734	4/20	0.66

▸	NMBR	P28336	1/20	0.63

▸	GRPR	P30550	1/20	0.63

▸	OPRM1	P35372	1/20	0.62

▸	OPRK1	P41145	1/20	0.62

▸	NTSR1	P30989	2/20	0.62

▸	PCSK9	Q8NBP7	1/20	0.62

▸	NTSR2	O95665	1/20	0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Dynorphin A (1-17) SCHEMBL29358748	1.00	OPRD1 (0.70)	OPRD1F2NMBRGRPROPRM1
Dynorphin A (1-17) SCHEMBL30248363	0.94	NPY1R (0.68)	OPRD1
Dynorphin A (1-17) SCHEMBL31331988	0.94	NPY1R (0.68)	OPRD1
SCHEMBL30589447	0.91	CXCR4 (0.68)	OPRD1
SCHEMBL30648474	0.89	NPY1R (0.66)	F2
Dynorphin A (1-11) SCHEMBL30132402	0.89	OPRD1 (0.86)	OPRD1OPRM1OPRK1NTSR1NTSR2
Analog Of Dynorphin A SCHEMBL29389694	0.89	OPRD1 (0.86)	OPRD1OPRM1OPRK1NTSR1NTSR2
SCHEMBL31182657	0.88	NPY1R (0.68)	—
SCHEMBL29878209	0.88	OPRD1 (0.85)	OPRD1OPRM1OPRK1NTSR1NTSR2
SCHEMBL29491173	0.88	C5AR1 (0.65)	OPRD1F2NMBRGRPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20250179130-A1	METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS	ON TARGET THERAPEUTICS LLC	2025-06-05	—	—	US	disclosed
US-20240301023-A1	PEPTIDES AND USES THEREOF	PreveCeutical Medical Inc. (CA)	2024-09-12	—	—	US	disclosed
US-12060397-B2	Soluble lipidated ligand agents for treating eye inflammation	TUFTS MEDICAL CENTER (US)	2024-08-13	—	—	US	disclosed
EP-4175970-A1	PEPTIDES AND USES THEREOF	Preveceutical Medical Inc. (CA)	2023-05-10	—	—	EP	disclosed
US-20220135633-A1	METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS	ON TARGET THERAPEUTICS LLC	2022-05-05	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20240301023-A1	PEPTIDES AND USES THEREOF	OPRL1, OPRK1, OPRM1	OPRD1 4/4885F2 3463/4885NMBR 196/4885
US-20220135633-A1	METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS	LDLR, HDLBP, LIPG	OPRD1 2716/4885F2 835/4885NMBR 1416/4885
US-20250179130-A1	METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS	LDLR, HDLBP, LIPG	OPRD1 2716/4885F2 835/4885NMBR 1416/4885
US-12060397-B2	Soluble lipidated ligand agents for treating eye inflammation	LIPG, CD40, LDLR	OPRD1 2797/4885F2 1454/4885NMBR 1403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.